Translating Psychedelic Experiences Into Targeted Health Outcomes: Optimism And Concern

A panel of executives, academics and experts discussed the potential for psychedelic therapies, such as MDMA and psilocybin, to revolutionize behavioral health in a recent Demy Colton virtual salon. But with nearly 50 publicly traded companies now developing psychedelics, some panelists expressed concern about a rush to market, and “competition and domination” harshening the buzz.

psychedelic image

Treating mental health disorders, such as addiction, depression, schizophrenia or post-traumatic stress disorder (PTSD), has not been as simple as swallowing a pill. The complexity of these disorders, and the factors that give rise to them – experiences of trauma, genetics, neurohormones and brain chemistry, interpersonal relationships, other illnesses (and other medications), and plenty of unknowns – demand a holistic approach to healing. With psychedelic therapies, that means understanding the subjective experiences of patients, and helping to guide them toward an intended outcome, not just during treatment, but before and afterward as well.

Panelists participating in Demy Colton’s virtual salon, Psychedelics Get Serious, emphasized the importance of “set and setting,” which includes a patient’s intentions when coming in for treatment, the location and environment where the treatment takes place, and a therapist’s role in facilitating a positive outcome

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Intelligence

ML-Assisted Genetic Risk Score Predicts GLP-1 Toxicity

 
• By 

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

Future Of 340B Rebate Models Hinges On Regulatory Decision Point

 
• By 

As pharmaceutical companies seek to transform how drug discounts are delivered under the 340B program, a federal ruling reinforces HRSA's authority. The industry must now wait for critical guidance from the Trump administration that could reshape compliance strategies and financial outcomes.

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By 

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Execs On The Move: April 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

More from In Vivo

Execs On The Move: April 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By 

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.